Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
Andre F, Nahta R, Conforti R, Boulet T, Aziz M, Yuan LX, Meslin F, Spielmann M, Tomasic G, Pusztai L, Hortobagyi GN, Michiels S, Delaloge S, Esteva FJ. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Annals Of Oncology 2007, 19: 315-320. PMID: 17804473, DOI: 10.1093/annonc/mdm429.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedBiomarkers, TumorBreast NeoplasmsChi-Square DistributionCohort StudiesCombined Modality TherapyDisease-Free SurvivalErbB ReceptorsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansImmunohistochemistryMiddle AgedNeoplasm StagingPredictive Value of TestsProbabilityProportional Hazards ModelsProto-Oncogene Proteins c-aktRandomized Controlled Trials as TopicReceptor, ErbB-2Risk AssessmentSurvival AnalysisTime FactorsTreatment OutcomeConceptsEarly breast cancerBreast cancerPredictive valuePhosphorylated AktAdjuvant chemotherapyPAkt expressionAnthracycline-based adjuvant chemotherapyEarly-stage breast cancerEpidermal growth factor receptor expressionGrowth factor receptor expressionAkt phosphorylationBreast cancer tissuesFactor receptor expressionGrowth factor receptorHER2 tumorsRandomized trialsAssessable tumorsHER2 expressionReceptor expressionPositive stainingCancer tissuesEGFR expressionHER2Tumor resistancePatientsHER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer
Pusztai L, Andre F, Mazouni C, Liedtke C, Kau S, Frye D, Green M, Gonzalez-Angulo A, Symmans W, Hortobagyi G. HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer. Journal Of Clinical Oncology 2007, 25: 548-548. DOI: 10.1200/jco.2007.25.18_suppl.548.Peer-Reviewed Original ResearchPathologic complete responseHER2 overexpressionPCR rateBreast cancerER- cancersHER2- diseaseHER2 expressionRelapse-free survival rateER-negative statusWeekly paclitaxel regimenMicrotubule associated protein tauHigh nuclear gradePaclitaxel regimenPreoperative paclitaxelFAC chemotherapyPreoperative chemotherapyComplete responseHER2 tumorsHER2 statusDoxorubicin chemotherapyNuclear gradeRetrospective analysisPatientsTaxane sensitivitySurvival rateProspective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes
Ueno N, Kim S, Symmans W, Detry M, Pusztai L, Sanchez L, Ishihara H, Hortobagyi G, Noguchi S. Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes. Journal Of Clinical Oncology 2007, 25: 586-586. DOI: 10.1200/jco.2007.25.18_suppl.586.Peer-Reviewed Original ResearchClinical responseTaxane sensitivityPreoperative therapyPrognostic factorsHER2 tumorsProspective studyBreast cancerDocetaxel/capecitabineDocetaxel/doxorubicinTaxane-containing regimensLarge prospective studiesPrimary breast cancerClinical prognostic factorsHER2- breast cancerNovel predictive markerCyclin-dependent kinase 1Breast tumor responseLogistic regression modelsEvaluable ptsAdjuvant therapyClinical outcomesPreclinical findingsPredictive markerTumor responseHER2 overexpressionHER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Research And Treatment 2007, 108: 183-190. PMID: 17468948, DOI: 10.1007/s10549-007-9594-8.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclophosphamideDisease-Free SurvivalDNA Topoisomerases, Type IIDNA-Binding ProteinsDoxorubicinDrug Administration ScheduleFemaleFluorouracilGene AmplificationGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedNeoadjuvant TherapyNeoplasm StagingOligonucleotide Array Sequence AnalysisPaclitaxelPatient SelectionPoly-ADP-Ribose Binding ProteinsReceptor, ErbB-2Receptors, EstrogenRetrospective StudiesRNA, MessengerTau ProteinsTime FactorsTreatment OutcomeConceptsPathologic complete responseHER2 overexpressionBreast cancerFAC chemotherapyPCR rateER statusHER2 expressionRelapse-free survival rateHER2-overexpressing breast cancerMicrotubule associated protein tauER-positive cancersEstrogen receptor statusPreoperative chemotherapyComplete responseHER2 tumorsMethodsRetrospective analysisReceptor statusPatientsSurvival rateMultivariate analysisWeekly scheduleMAP-tauProtein tauCancerChemotherapy